Tildrakizumab
- Part D specialty tier in 79% of formularies (2026Q3)
- Biologic
- ILUMYA
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Tildrakizumab: storage and handling
- Refrigerate
- Yes, as the label states
Label statement
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use.
- Freezing
- Do not freeze
Label statement
Do not freeze.
- Room temperature
- up to 30 days at or below 25°C (77°F)
Label statement
ILUMYA can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton to protect from light.
- Back into the refrigerator
- Not allowed
Label statement
Once stored at room temperature, do not place back in the refrigerator.
- Light
- Protect from light
Label statement
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use.
- Shaking
- Do not shake
Label statement
Do not shake.
All storage statements on the label (7)
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use.
- Do not freeze.
- Do not shake.
- ILUMYA can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton to protect from light.
- Once stored at room temperature, do not place back in the refrigerator.
- If not used within 30 days, discard ILUMYA.
- Do not store ILUMYA above 25°C (77°F).
FDA label version 19, effective July 29, 2026. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.